2 Sources
[1]
SCP-Nano: New technology visualizes nanocarriers in cells and tissues
by Verena Schulz, Helmholtz Association of German Research Centres How can we ensure that life-saving drugs or genetic therapies reach their intended target cells without causing harmful side effects? Researchers at Helmholtz Munich, Ludwig-Maximilians-Universität (LMU) and Technical University Munich (TUM) have developed a method that, for the first time, enables the precise detection of nanocarriers -- tiny transport vehicles -- throughout the entire mouse body at a single-cell level. This innovation, called Single-Cell Profiling of Nanocarriers or SCP-Nano, combines advanced imaging with artificial intelligence to provide unparalleled insights into the functionality of nanotechnology-based therapies. The results, published in Nature Biotechnology, pave the way for safer and more effective treatments, including mRNA vaccines and gene therapies. The role of nanocarriers in modern medicine Nanocarriers will play a central role in the next wave of life-saving medicines. They enable the targeted delivery of drugs, genes, or proteins to cells within patients. With SCP-Nano, researchers can analyze the distribution of extremely low doses of nanocarriers throughout the entire mouse body, visualizing each cell that has taken them up. SCP-Nano combines optical tissue clearing, light-sheet microscopy imaging, and deep-learning algorithms. First, whole mouse bodies are made transparent. After the three-dimensional imaging of whole mouse bodies, nanocarriers within the transparent tissues can then be identified down to the single-cell level. By integrating AI-based analysis, researchers can quantify which cells and tissues are interacting with the nanocarriers and precisely where this occurs. Practical applications of SCP-Nano Examples of nanocarriers analyzed by Ali Ertürk, the director of the Institute for Intelligent Biotechnologies (iBIO) at Helmholtz Munich, and his team using SCP-Nano include lipid nanoparticles (LNPs), DNA origami structures and adeno-associated viruses (AAVs). These nanocarriers are essential for modern therapeutics that address diseases at their cellular roots, each possessing unique properties that make them suitable for different applications. DNA origami structures are easily programmable and AAVs are highly efficient carriers for gene therapy. The LNPs facilitate RNA delivery, which underlies modern mRNA vaccines and a broad range of other RNA therapeutics. Using SCP-Nano, the researchers demonstrated that DNA origami structures can be preferentially targeted to the immune cells, while AAV variants target distinct brain regions and adipose tissue. Importantly, the platform also revealed that lipid nanoparticles carrying mRNA therapeutics can accumulate in heart tissue. Thus, using SCP-Nano, researchers can now detect potentially problematic off-target tissues and associated toxicities before they enter clinical trials, paving the way for the development of safer mRNA therapeutics. Visualizing nanocarriers with unprecedented precision "With SCP-Nano, we can detect nanocarriers throughout the body in incredibly low doses, down to 0.0005 mg/kg," says the study's first author, Dr. Jie Luo. "This gives us an entirely new perspective on how these tiny transport vehicles interact with organs and cells." Luo emphasizes that it is especially important that SCP-Nano can identify unwanted accumulation in the heart or liver. The mechanism of nanocarriers is comparable to a parcel delivery service, Ertürk explains, "Each nanocarrier is like a package carrying an important payload that must be delivered to the exact right apartment, not just the one next door. SCP-Nano allows us to track exactly where these packages are delivered, whether they reach their precise intended destination, or if they accidentally end up in unwanted locations." Driving innovation in personalized medicine SCP-Nano allows researchers to precisely identify where nanocarriers accumulate and to visualize their interactions with target cells- a key requirement for safe and effective nanocarrier applications. "SCP-Nano will not only help assess the safety of existing nanocarriers but also drive the development of new, highly targeted applications," says Luo. "The platform can also help to monitor the success of mRNA therapies or detect potential side effects early." By combining cutting-edge imaging and AI technologies, SCP-Nano offers researchers and clinicians a new level of understanding of how therapies interact with the body and can easily be extended to human tissues and organs. "Precision medicine and targeted delivery are often discussed, but scalable and effective tools for this have been limited. This new approach offers a solution to a key challenge in drug development," concludes Prof. Ertürk. With its potential to minimize side effects and enhance treatment precision, SCP-Nano marks an important step toward safer and more effective therapies in fields like cancer treatment, gene therapy, and vaccine development. This innovation not only addresses major challenges in the development of nanocarrier-based technologies but also drives the future of precision medicine.
[2]
SCP-Nano: A new technology to visualize nanocarriers in cells and tissues
How can we ensure that life-saving drugs or genetic therapies reach their intended target cells without causing harmful side effects? Researchers at Helmholtz Munich, Ludwig-Maximilians-Universität (LMU) and Technical University Munich (TUM) have taken an important step to answer this question. They have developed a method that, for the first time, enables the precise detection of nanocarriers -- tiny transport vehicles -- throughout the entire mouse body at a single-cell level. This innovation, called "Single-Cell Profiling of Nanocarriers" or short "SCP-Nano," combines advanced imaging with artificial intelligence to provide unparalleled insights into the functionality of nanotechnology-based therapies. The results, published in Nature Biotechnology, pave the way for safer and more effective treatments, including mRNA vaccines and gene therapies. Nanocarriers will play a central role in the next wave of life-saving medicines. They enable the targeted delivery of drugs, genes, or proteins to cells within patients. With SCP-Nano, researchers can analyze the distribution of extremely low doses of nanocarriers throughout the entire mouse body, visualizing each cell that has taken them up. SCP-Nano combines optical tissue clearing, light-sheet microscopy imaging, and deep-learning algorithms. First, whole mouse bodies are made transparent. After the three-dimensional imaging of whole mouse bodies, nanocarriers within the transparent tissues can then be identified down to the single-cell level. By integrating AI-based analysis, researchers can quantify which cells and tissues are interacting with the nanocarriers and precisely where this occurs. Practical Applications of SCP-Nano Examples of nanocarriers analyzed by Ali Ertürk, the director of the Institute for Intelligent Biotechnologies (iBIO) at Helmholtz Munich, and his team using SCP-Nano include lipid nanoparticles (LNPs), DNA origami structures and adeno-associated viruses (AAVs). These nanocarriers are essential for modern therapeutics that address diseases at their cellular roots, each possessing unique properties that make them suitable for different applications. DNA origami structures are easily programmable and AAVs are highly efficient carriers for gene therapy. The LNPs facilitate RNA delivery, which underlies modern mRNA vaccines and a broad range of other RNA therapeutics. Using SCP-Nano, the researchers demonstrated that DNA origami structures can be preferentially targeted to the immune cells, while AAV variants target distinct brain regions and adipose tissue. Importantly, the platform also revealed that lipid nanoparticles carrying mRNA therapeutics can accumulate in heart tissue. Thus, using SCP-Nano researchers can now detect potentially problematic off-target tissues and associated toxicities before they enter clinical trials, paving the way for the development of safer mRNA therapeutics. Visualizing Nanocarriers with Unprecedented Precision "With SCP-Nano, we can detect nanocarriers throughout the body in incredibly low doses, down to 0.0005 mg/kg," says the study's first author, Dr. Jie Luo. "This gives us an entirely new perspective on how these tiny transport vehicles interact with organs and cells." Luo emphasizes that it is especially important that SCP-Nano can identify unwanted accumulation in the heart or liver. The mechanism of nanocarriers is comparable to a parcel delivery service, Ertürk explains: "Each nanocarrier is like a package carrying an important payload that must be delivered to the exact right apartment, not just the one next door. SCP-Nano allows us to track exactly where these packages are delivered, whether they reach their precise intended destination, or if they accidentally end up in unwanted locations." Driving Innovation in Personalized Medicine SCP-Nano allows researchers to precisely identify where nanocarriers accumulate and to visualize their interactions with target cells- a key requirement for safe and effective nanocarrier applications. "SCP-Nano will not only help assess the safety of existing nanocarriers but also drive the development of new, highly targeted applications," says Luo. "The platform can also help to monitor the success of mRNA therapies or detect potential side effects early." A New Era for Drug Development and Personalized Therapies By combining cutting-edge imaging and AI technologies, SCP-Nano offers researchers and clinicians a new level of understanding of how therapies interact with the body and can easily be extended to human tissues and organs. "Precision medicine and targeted delivery are often discussed, but scalable and effective tools for this have been limited. This new approach offers a solution to a key challenge in drug development," concludes Prof. Ertürk. With its potential to minimize side effects and enhance treatment precision, SCP-Nano marks an important step toward safer and more effective therapies in fields like cancer treatment, gene therapy, and vaccine development. This innovation not only addresses major challenges in the development of nanocarrier-based technologies but also drives the future of precision medicine.
Share
Copy Link
Researchers develop SCP-Nano, an innovative method combining advanced imaging and AI to precisely detect nanocarriers throughout the entire mouse body, paving the way for safer and more effective targeted therapies.
Researchers at Helmholtz Munich, Ludwig-Maximilians-Universität (LMU), and Technical University Munich (TUM) have developed a groundbreaking technology called Single-Cell Profiling of Nanocarriers (SCP-Nano). This innovative method enables the precise detection of nanocarriers throughout the entire mouse body at a single-cell level, marking a significant advancement in the field of targeted drug delivery and gene therapy 1.
SCP-Nano combines optical tissue clearing, light-sheet microscopy imaging, and deep-learning algorithms to achieve unprecedented precision in visualizing nanocarriers. The process involves:
This technology can detect nanocarriers in incredibly low doses, down to 0.0005 mg/kg, providing researchers with a new perspective on how these tiny transport vehicles interact with organs and cells 2.
SCP-Nano has been successfully used to analyze various types of nanocarriers, including:
Each of these nanocarriers has unique properties suitable for different applications in modern therapeutics. The research team, led by Ali Ertürk, director of the Institute for Intelligent Biotechnologies (iBIO) at Helmholtz Munich, demonstrated that:
These findings highlight the potential of SCP-Nano to detect off-target tissues and associated toxicities before clinical trials, paving the way for safer mRNA therapeutics and other targeted treatments 1.
SCP-Nano's ability to precisely identify nanocarrier accumulation and visualize their interactions with target cells is crucial for developing safe and effective nanocarrier applications. Dr. Jie Luo, the study's first author, emphasizes that this technology will not only help assess the safety of existing nanocarriers but also drive the development of new, highly targeted applications 2.
The development of SCP-Nano marks an important step toward safer and more effective therapies in fields such as:
By combining cutting-edge imaging and AI technologies, SCP-Nano offers researchers and clinicians a new level of understanding of how therapies interact with the body. This innovation addresses major challenges in the development of nanocarrier-based technologies and drives the future of precision medicine 1 2.
Databricks raises $1 billion in a new funding round, valuing the company at over $100 billion. The data analytics firm plans to invest in AI database technology and an AI agent platform, positioning itself for growth in the evolving AI market.
11 Sources
Business
14 hrs ago
11 Sources
Business
14 hrs ago
SoftBank makes a significant $2 billion investment in Intel, boosting the chipmaker's efforts to regain its competitive edge in the AI semiconductor market.
22 Sources
Business
22 hrs ago
22 Sources
Business
22 hrs ago
OpenAI introduces ChatGPT Go, a new subscription plan priced at ₹399 ($4.60) per month exclusively for Indian users, offering enhanced features and affordability to capture a larger market share.
15 Sources
Technology
22 hrs ago
15 Sources
Technology
22 hrs ago
Microsoft introduces a new AI-powered 'COPILOT' function in Excel, allowing users to perform complex data analysis and content generation using natural language prompts within spreadsheet cells.
8 Sources
Technology
14 hrs ago
8 Sources
Technology
14 hrs ago
Adobe launches Acrobat Studio, integrating AI assistants and PDF Spaces to transform document management and collaboration, marking a significant evolution in PDF technology.
10 Sources
Technology
14 hrs ago
10 Sources
Technology
14 hrs ago